Volume 4, Issue 8
Combination therapy of uterine cervical ectopy in young nulliparous women
I. Kupchak, N. Genyk
Actuality of the study of cervical pathology is caused by a significant degree of abnormality detection in young nullipara and the probability of further malignancy, especially if it is associated with papillomavirus infection. According to the literature data uterine cervical ectopy occurs in 38.8 % of the female population and in 54.2 % of gynecological patients; 49.2 % of women with ectopy are under 25 years of age. Increasing frequency of cervical pathology background in nulliparous women, correlates to the growth of diseases of the genital system, sexually transmitted infections, including human papillomavirus of high oncogenous risk. These abnormal conditions attract practitioners’ and scientists’ attention, as they can be the basis of malignancy. The research is based on examination of 52 nulliparous women from 18 to 25 years of age (average age was 22.3 ± 0.42 years) with diagnosed cervical ectopy on the background of hormonal dysfunction. Depending on the chosen treatment, women were divided into 2 groups. Group I included 25 women. They were made argon plasma coagulation on the 5th-7th day of menstrual cycle, depending on the duration of their menstrual discharge. The treatment in this group of patients was characterized by the administration of hormonal contraceptive drug "Jazz plus" from the first day of the menstrual cycle on which APC was scheduled, with further drug administration for the period of 6 months. Group II counted 27 women, who were made the argon plasma coagulation only. The use of minipill hormone oral contraceptive combined with argon plasma coagulation of the cervix in young women provides an opportunity to accelerate regeneration processes of multilayer squamous epithelium and normalize the menstrual function and level of sex hormones.
Download Full Article: Click Here
Support Us
If you are interested in supporting our work and would like to contribute, you are welcome to mail me at jpbr.anil@gmail.com or at info@thepharmajournal.com it will be a great help and will surely be appreciated.
